Brent crude oil jumped the most in history in the previous session after attacks on Saudi's oil industry disrupted the kingdom's production.Marketsread more
Damage to the top OPEC producer's oil facilities ignited fears of supply disruption around the world and has sent crude prices soaring.Energyread more
The second-largest investor in Kraft Heinz Company discloses that it has again trimmed its stake in the food company.Marketsread more
Consumers could pay an average 15 to 20 cents more per gallon for unleaded gas by the end of the month following the attack on Saudi oil installations.Market Insiderread more
Pelosi also said it's "irrelevant" whether approving the USMCA trade deal would give President Donald Trump a victory ahead of the 2020 election.Politicsread more
Elliott Management may not see John Stankey as a future leader at AT&T, but bailing on him before he executes his integration plan has the potential for disaster.Technologyread more
The White House directed Lewandowski not to discuss any of his post-election interactions with Trump beyond those already detailed in former special counsel Robert Mueller's...Politicsread more
Tension between the real estate start-up WeWork and SoftBank was not a central issue in the decision to delay an initial public offering, sources tell CNBC's David FaberThe Faber Reportread more
The service will debut in April with pricing to be announced closer to the launch data, NBCUniversal says.Technologyread more
"Jeopardy!" host Alex Trebek says he's had a setback in his battle with pancreatic cancer and is undergoing chemotherapy again.Entertainmentread more
A sharp drop in mortgage rates in August was clearly behind the confidence in September. The survey came with warning signs, however. Mortgage rates shot back up at the start...Real Estateread more
(Adds details on the delay, analyst comment, updates share movement)
June 24 (Reuters) - Bristol-Myers Squibb Co on Monday offered to divest Celgene Corp's psoriasis treatment Otezla to allay concerns raised by the U.S. competition regulator, and pushed back the closing of their $74 billion deal.
The surprise move sent Bristol's shares down 4.3% in morning trading, while Celgene fell nearly 4%.
Bristol announced its plans to buy Celgene in a cash-and-stock deal in early January to bring together the companies that specialize in oncology and cardiovascular drugs in the largest pharmaceutical industry merger ever. It had said it would close the deal in the third quarter of 2019.
However, now it expects the merger to close by the end of 2019 or the beginning of 2020.
The divestiture is subject to further review by the U.S. Federal Trade Commission (FTC) and requires Bristol to enter into a consent decree with the agency, Bristol said.
In March, the FTC had sought additional information from the companies as it focused on their psoriasis treatments as part of its review of their planned merger.
Otezla brought in revenue of $1.61 billion for Celgene in 2018. Bristol is also developing a treatment for the condition and in September reported positive results from a mid-stage trial of its plaque psoriasis drug.
"The company is continuing to develop its promising immunology pipeline asset, tyrosine kinase 2 (TYK2) inhibitor, in several autoimmune diseases, including psoriasis," Bristol said in a statement.
Jefferies analyst Michael Yee said the divestiture came as a surprise to the brokerage and can be seen as a sign that the FTC is being tougher on regulating competition.
Bristol said it remains actively engaged in discussions with the FTC on continued review of its offer to buy Celgene.
Separately on Monday, Bristol said its blockbuster cancer treatment Opdivo failed to meet the main goal of statistically significant improvement in overall survival in patients in a late-stage study.
The companies have submitted a formal application for the merger clearance by the European Commission, Bristol said. (Reporting by Aakash Jagadeesh Babu in Bengaluru; Editing by Shinjini Ganguli)